Literature DB >> 15137074

Perfusion cultures of human tumor cells: a scalable production platform for oncolytic adenoviral vectors.

Inn H Y Yuk1, Matthew M Olsen, Scott Geyer, Sean P Forestell.   

Abstract

This study demonstrates the novel use of the HeLaS3 human tumor cell line for propagating ONYX-411, a recombinant oncolytic adenoviral vector. HeLaS3 cells enabled high levels of vector production without the risk of generating vector recombinants, which is possible with HEK293 cells. The development of a high-cell-density perfusion process using ATF technology yielded production levels as high as 6 x 10(11) vp/mL, which was approximately sevenfold greater than the titers achieved in fed-batch bioreactors. Several experiments were performed at the bench (15 L) and pilot (70 L) scales to demonstrate the robust and scalable nature of this industrially relevant technology. Copyright 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15137074     DOI: 10.1002/bit.20158

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  8 in total

1.  Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques.

Authors:  Stéphane Carlier; Ioannis A Kakadiaris; Nabil Dib; Manolis Vavuranakis; Sean M O'Malley; Khawar Gul; Craig J Hartley; Ralph Metcalfe; Roxana Mehran; Christodoulos Stefanadis; Erling Falk; Gregg Stone; Martin Leon; Morteza Naghavi
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

2.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

3.  A serum-free Vero production platform for a chimeric virus vaccine candidate.

Authors:  Inn H Yuk; Gina B Lin; Hui Ju; Inesse Sifi; Yvonne Lam; Armida Cortez; Danny Liebertz; J Michael Berry; Richard M Schwartz
Journal:  Cytotechnology       Date:  2006-11-16       Impact factor: 2.058

4.  Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.

Authors:  Allen Chen; Swan Li Poh; Christian Dietzsch; Elisabeth Roethl; Mylene L Yan; Say Kong Ng
Journal:  BMC Biotechnol       Date:  2011-08-11       Impact factor: 2.563

5.  Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor™. Part I. Effect of the cell density on the process.

Authors:  Marie-Françoise Clincke; Carin Mölleryd; Ye Zhang; Eva Lindskog; Kieron Walsh; Véronique Chotteau
Journal:  Biotechnol Prog       Date:  2013-05-21

6.  Very high density of Chinese hamster ovary cells in perfusion by alternating tangential flow or tangential flow filtration in WAVE Bioreactor™-part II: Applications for antibody production and cryopreservation.

Authors:  Marie-Françoise Clincke; Carin Mölleryd; Puneeth K Samani; Eva Lindskog; Eric Fäldt; Kieron Walsh; Véronique Chotteau
Journal:  Biotechnol Prog       Date:  2013-05-21

Review 7.  Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.

Authors:  Felipe Tapia; Daniel Vázquez-Ramírez; Yvonne Genzel; Udo Reichl
Journal:  Appl Microbiol Biotechnol       Date:  2016-01-13       Impact factor: 4.813

8.  High-cell-density cultivations to increase MVA virus production.

Authors:  Daniel Vázquez-Ramírez; Yvonne Genzel; Ingo Jordan; Volker Sandig; Udo Reichl
Journal:  Vaccine       Date:  2018-02-09       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.